CAR-T Cells for the Treatment of Lung Cancer.
CAR-T
adoptive cell therapy
immunotherapy
lung cancer
solid tumors
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
08 Apr 2022
08 Apr 2022
Historique:
received:
23
02
2022
revised:
05
04
2022
accepted:
06
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors (CAR-T) is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in hematological malignancies. However, the efficacy of CAR-T cells in solid tumors is still very unsatisfactory, because of the strong immunosuppressive tumor microenvironment that hinders immune responses. The development of next-generation personalized CAR-T cells against solid tumors is a clinical necessity. The identification of therapeutic targets for new CAR-T therapies to increase the efficacy, survival, persistence, and safety in solid tumors remains a critical frontier in cancer immunotherapy. Here, we summarize basic, translational, and clinical results of CAR-T cell immunotherapies in lung cancer, from their molecular engineering and mechanistic studies to preclinical and clinical development.
Identifiants
pubmed: 35455052
pii: life12040561
doi: 10.3390/life12040561
pmc: PMC9028981
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Asociación Española Contra el Cáncer
ID : AECC, PROYE16001ESCO
Références
Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):107-19
pubmed: 20143172
Oncol Lett. 2018 Dec;16(6):6998-7007
pubmed: 30546433
J Exp Med. 2006 Jul 10;203(7):1651-6
pubmed: 16801397
Cancer Treat Rev. 2018 Jun;67:54-62
pubmed: 29763778
J Immunother Cancer. 2019 Dec 16;7(1):351
pubmed: 31843013
Lung Cancer. 2012 May;76(2):138-43
pubmed: 22153832
Cancer Immunol Immunother. 2017 Nov;66(11):1449-1461
pubmed: 28707078
Nat Rev Cancer. 2003 Jan;3(1):35-45
pubmed: 12509765
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
J Clin Invest. 2016 Oct 3;126(10):3814-3826
pubmed: 27571406
Oncoimmunology. 2017 Feb 6;6(3):e1284722
pubmed: 28405515
J Thorac Dis. 2010 Mar;2(1):48-51
pubmed: 22263017
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
J Clin Invest. 2013 Apr;123(4):1732-40
pubmed: 23454747
BMC Pulm Med. 2021 Jun 10;21(1):199
pubmed: 34112123
Mol Ther Nucleic Acids. 2013 Jul 09;2:e105
pubmed: 23839099
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Transfus Med Hemother. 2019 Feb;46(1):15-24
pubmed: 31244578
Mol Ther. 2013 Nov;21(11):2087-101
pubmed: 23939024
J Hematol Oncol. 2019 Jun 10;12(1):57
pubmed: 31182121
Int J Mol Sci. 2018 Jan 30;19(2):
pubmed: 29385713
Oncotarget. 2018 Nov 2;9(86):35666-35675
pubmed: 30479696
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32554616
Clin Cancer Res. 2013 Jan 15;19(2):462-8
pubmed: 23169436
Biochem Soc Trans. 2016 Apr 15;44(2):412-8
pubmed: 27068948
Nat Med. 2003 Mar;9(3):279-86
pubmed: 12579196
Transl Lung Cancer Res. 2019 Aug;8(4):352-366
pubmed: 31555511
Expert Opin Biol Ther. 2015;15(8):1145-54
pubmed: 25985798
J Immunol Res. 2018 Aug 8;2018:6984948
pubmed: 30159341
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Transl Res. 2017 Sep;187:1-10
pubmed: 28502785
Cancer Sci. 2019 May;110(5):1599-1608
pubmed: 30874360
Cancer Sci. 2018 Jan;109(1):141-153
pubmed: 29151270
J Cell Physiol. 2019 Jul;234(7):12080-12086
pubmed: 30569450
Respir Res. 2019 May 29;20(1):106
pubmed: 31142317
Oncogene. 2021 Jan;40(1):1-11
pubmed: 33060857
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8
pubmed: 2513569
Oncotarget. 2014 Sep 15;5(17):7843-57
pubmed: 25151659
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Stem Cell Res Ther. 2021 Jan 25;12(1):81
pubmed: 33494834
Nat Rev Cancer. 2021 Mar;21(3):145-161
pubmed: 33483715
PLoS One. 2017 Oct 27;12(10):e0186280
pubmed: 29077706
Genet Mol Res. 2015 Aug 28;14(3):10185-92
pubmed: 26345955
Blood. 2008 Sep 15;112(6):2261-71
pubmed: 18509084
BMC Cancer. 2013 May 22;13:254
pubmed: 23697613
World J Surg Oncol. 2012 Apr 06;10:53
pubmed: 22482828
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Neuro Oncol. 2018 Mar 27;20(4):506-518
pubmed: 29016929
Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):113-123
pubmed: 29032490
Cancer Lett. 2022 Mar 31;529:70-84
pubmed: 34971753
N Engl J Med. 1992 Jul 2;327(1):14-8
pubmed: 1317941
J Cancer Res Clin Oncol. 2021 Dec;147(12):3725-3734
pubmed: 34032893
BMC Cancer. 2020 Jun 29;20(1):606
pubmed: 32600281
Cancer Res. 2012 Nov 1;72(21):5556-65
pubmed: 22986740
Exp Ther Med. 2017 Nov;14(5):4443-4447
pubmed: 29104655
J Clin Oncol. 2011 Dec 20;29(36):4828-36
pubmed: 22042955
PLoS One. 2015 May 15;10(5):e0125924
pubmed: 25978404
Oncogenesis. 2020 Aug 13;9(8):72
pubmed: 32792499
EMBO Mol Med. 2017 Sep;9(9):1183-1197
pubmed: 28765140
Clin Cancer Res. 2018 Jun 1;24(11):2594-2604
pubmed: 29298799
J Hematol Oncol. 2017 Jan 5;10(1):4
pubmed: 28057014
J Pers Med. 2021 Jun 11;11(6):
pubmed: 34208043
J Hematol Oncol. 2019 Oct 22;12(1):106
pubmed: 31640756
Int J Cancer. 2014 Nov 1;135(9):2206-14
pubmed: 24710653
Biomark Res. 2020 Jun 03;8:19
pubmed: 32514352
Int J Clin Exp Pathol. 2015 Nov 01;8(11):13987-95
pubmed: 26823710
Clin Cancer Res. 2008 Dec 1;14(23):7624-34
pubmed: 19047087
J Hematol Oncol. 2020 Jul 2;13(1):86
pubmed: 32616000
Int J Mol Sci. 2021 May 17;22(10):
pubmed: 34067904
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Mol Cancer. 2017 Mar 14;16(1):63
pubmed: 28288645
Int J Biol Sci. 2020 Mar 25;16(11):1767-1773
pubmed: 32398947
Neoplasia. 2005 Dec;7(12):1058-64
pubmed: 16354588
Int J Mol Sci. 2020 Mar 31;21(7):
pubmed: 32244396
Cancer Res. 2014 Jan 1;74(1):263-71
pubmed: 24395821
J Clin Invest. 2012 Mar;122(3):899-910
pubmed: 22293174
Lung Cancer. 2004 Oct;46(1):11-9
pubmed: 15364128
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986912
Oncogene. 2019 Sep;38(37):6399-6413
pubmed: 31324888
Nat Rev Drug Discov. 2015 Jul;14(7):499-509
pubmed: 26129802
Annu Rev Pathol. 2011;6:49-69
pubmed: 20887192
N Engl J Med. 2016 Jun 30;374(26):2542-52
pubmed: 27093365
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Nat Genet. 2012 Jul 01;44(8):852-60
pubmed: 22751098
Gene Ther. 2010 Jun;17(6):721-32
pubmed: 20164855
Signal Transduct Target Ther. 2019 Sep 20;4:35
pubmed: 31637014
Cancer Res. 2001 May 15;61(10):4244-52
pubmed: 11358851
Lung Cancer. 2006 Aug;53(2):143-51
pubmed: 16782226
Int J Mol Sci. 2018 Nov 15;19(11):
pubmed: 30445777
Front Immunol. 2020 Jun 17;11:1109
pubmed: 32625204
Cancer Cell. 2012 Jun 12;21(6):836-47
pubmed: 22698407
Front Immunol. 2020 Mar 05;11:176
pubmed: 32194541
Front Immunol. 2021 Mar 11;12:628906
pubmed: 33777013
J Clin Invest. 2019 Jul 2;129(8):3464
pubmed: 31264975
Cytotherapy. 2006;8(6):542-53
pubmed: 17148030
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Am Soc Clin Oncol Educ Book. 2017;37:193-204
pubmed: 28561728
Cell Commun Signal. 2020 Apr 7;18(1):59
pubmed: 32264958
Int J Mol Sci. 2021 Apr 03;22(7):
pubmed: 33916696
Cancer J Sci Am. 1999 Jan-Feb;5(1):20-5
pubmed: 10188057
Front Immunol. 2021 Mar 05;12:609421
pubmed: 33767695
Mol Ther. 2007 Oct;15(10):1744-50
pubmed: 17637721
J Immunother. 2010 Oct;33(8):828-33
pubmed: 20842054
Front Pharmacol. 2014 Oct 28;5:235
pubmed: 25389405
Mol Ther. 2007 Apr;15(4):825-33
pubmed: 17299405
J Immunother. 2009 Apr;32(3):292-301
pubmed: 19242371
Immunol Rev. 2014 Jan;257(1):83-90
pubmed: 24329791
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
pubmed: 8421711
Science. 2006 Oct 6;314(5796):126-9
pubmed: 16946036
Front Oncol. 2021 May 28;11:680834
pubmed: 34123850
Ann Oncol. 2017 Jul 01;28(7):1605-1611
pubmed: 28419181
Expert Opin Biol Ther. 2007 Aug;7(8):1207-18
pubmed: 17696819
Cancer Res. 2011 Sep 1;71(17):5697-706
pubmed: 21742772
J Hematol Oncol. 2020 May 18;13(1):54
pubmed: 32423475
Expert Rev Anticancer Ther. 2016 Jul;16(7):677-9
pubmed: 27210575
EMBO Mol Med. 2019 Jul;11(7):e10293
pubmed: 31273938
Adv Exp Med Biol. 2021;1342:297-317
pubmed: 34972970
Anticancer Res. 2009 May;29(5):1817-22
pubmed: 19443410
Tissue Barriers. 2022 Jan 2;10(1):1967080
pubmed: 34486479
Oncotarget. 2015 Sep 29;6(29):27160-75
pubmed: 26320174
J Hematol Oncol. 2019 Jun 18;12(1):61
pubmed: 31215500
Cancer Immunol Res. 2016 Jun;4(6):498-508
pubmed: 27059623
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
pubmed: 17062687
J Hematol Oncol. 2018 Feb 13;11(1):22
pubmed: 29433552
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
J Thorac Dis. 2019 Jan;11(1):35-38
pubmed: 30863564
Int J Mol Sci. 2018 Aug 20;19(8):
pubmed: 30127261
Cancers (Basel). 2020 Feb 04;12(2):
pubmed: 32033028
Front Immunol. 2020 May 15;11:940
pubmed: 32499786